A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer.
暂无分享,去创建一个
Harald Frick | Nicole Probst-Hensch | N. Probst-Hensch | B. Thürlimann | M. Joerger | H. Frick | C. Bouchardy | I. Konzelmann | Beat Thürlimann | A. Savidan | S. Ess | Markus Joerger | Anita Savidan | Christine Bouchardy | Isabelle Konzelmann | Silvia Ess
[1] R. Gelber,et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. , 1995, Journal of the National Cancer Institute.
[2] R. Gelber,et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] D. Rose,et al. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. , 2009, Journal of women's health.
[4] J. Bryant,et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Tu,et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[7] Harold C. Sox,et al. National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making , 1988 .
[8] R. Gelber,et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Earl,et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. , 2006, The New England journal of medicine.
[10] N. Probst-Hensch,et al. Predictors of state-of-the-art management of early breast cancer in Switzerland. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] S. Schraub,et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Forman,et al. The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire's breast cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] S. Martino,et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.
[14] A. Carrato,et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Dongsheng Tu,et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Edge,et al. NCCN: Breast cancer. , 2001, Cancer control : journal of the Moffitt Cancer Center.
[17] Edith A Perez,et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Osborne,et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Forbes,et al. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 , 2008, Breast Cancer Research and Treatment.
[20] R. Gelber,et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. , 2002, Journal of the National Cancer Institute.
[21] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Delozier,et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] V. Bramwell,et al. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. , 1992, European journal of cancer.
[25] E. Perez,et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.
[26] J. Forbes,et al. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93 , 2009, Breast Cancer Research and Treatment.
[27] J. Griggs,et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Verkooijen,et al. Social class is an important and independent prognostic factor of breast cancer mortality , 2006, International journal of cancer.
[29] E. Perez,et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] G. Vlastos,et al. Geographic variation in breast cancer care in Switzerland. , 2010, Cancer epidemiology.
[31] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[32] R. Gelber,et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[34] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[35] C. Masi,et al. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] P. Rosenberg,et al. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. , 2009, Journal of the National Cancer Institute.
[37] R. Gelber,et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] A. Bordoni,et al. Variation in survival after diagnosis of breast cancer in Switzerland. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] L. Clegg,et al. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] V. Shavers,et al. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35 , 2003, Cancer.